BlueRock and bit.bio join forces on Treg-based therapies

German pharma major Bayer’s (BAYN: DE) independently-operated subsidiary BlueRock Therapeutics has entered into a collaboration and option agreement with machine learning-powered bit.bio for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.

Under the deal’s terms, bit.bio will use its machine learning powered discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. The agreement also includes options for BlueRock to license bit.bio’s opti-ox precision cell programming technology to control the expression of TF combinations within Treg cell therapies. opti-ox uses a dual genomic safe harbour approach to cell programming, and bit.bio uses opti-ox to drive the rapid TF-mediated conversion of iPSCs into highly defined cell types in a single step. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency.

BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from the collaboration. In return, bit.bio receives an undisclosed upfront payment and is eligible for milestones and royalties on worldwide sales of all therapies resulting from the collaboration.